Stockscreener 앱 받기
33.05
4.45%
-1.54
전일 마감가:
$34.59
열려 있는:
$34.74
하루 거래량:
755.25K
Relative Volume:
2.08
시가총액:
$1.82B
수익:
$651.97M
순이익/손실:
$59.71M
주가수익비율:
30.90
EPS:
1.0696
순현금흐름:
$172.03M
1주 성능:
-15.49%
1개월 성능:
-14.33%
6개월 성능:
-4.73%
1년 성능:
+17.45%
1일 변동 폭
$32.98
$34.87
1주일 범위
$32.53
$39.99
52주 변동 폭
$25.53
$40.28
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
명칭
Supernus Pharmaceuticals Inc
전화
301-838-2500
주소
9715 KEY WEST AVENUE, ROCKVILLE, MD
SUPN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
33.05 | 1.82B | 651.97M | 59.71M | 172.03M | 1.0696 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-19 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-09-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | 재개 | Jefferies | Buy |
| 2021-12-01 | 재개 | Jefferies | Buy |
| 2021-04-13 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-06-16 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | 재개 | Jefferies | Hold |
| 2019-11-08 | 다운그레이드 | Berenberg | Buy → Hold |
| 2019-11-07 | 다운그레이드 | Stifel | Buy → Hold |
| 2019-11-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-11-12 | 재확인 | B. Riley FBR | Buy |
| 2018-01-18 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | 업그레이드 | Janney | Neutral → Buy |
| 2017-11-08 | 업그레이드 | Stifel | Hold → Buy |
| 2017-10-19 | 개시 | FBR & Co. | Buy |
| 2017-09-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2017-07-17 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | 개시 | Janney | Neutral |
| 2017-06-01 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | 업그레이드 | Jefferies | Hold → Buy |
| 2015-11-05 | 재확인 | Northland Capital | Outperform |
| 2015-10-28 | 개시 | Northland Capital | Outperform |
모두보기
Supernus Pharmaceuticals Inc 주식(SUPN)의 최신 뉴스
New York State Teachers Retirement System Boosts Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus plunges as mid-stage trial for depression therapy fails - MSN
Supernus' depression treatment fails mid-stage trial, shares plunge - MSN
Depression failure sends Supernus shares downwards - The Pharma Letter
How the (SUPN) price action is used to our Advantage - Stock Traders Daily
Supernus phase IIb results drag down the stock - BioWorld Online
Cantor Fitzgerald cuts Supernus stock rating, target to $36 By Investing.com - Investing.com Canada
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial - AOL
Supernus’s stock sinks after depression drug fails trial - Yahoo
Sanofi reaches consumer health deal; Supernus antidepressant fails study - BioPharma Dive
BREAKING: Supernus Pharmaceuticals, Inc. Shares Down 14%; Investors Should Contact Block & ... - The Bakersfield Californian
BREAKING: Supernus Pharmaceuticals, Inc. Shares Down 14%; - GlobeNewswire
Supernus Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsSUPN - ACCESS Newswire
Supernus stock falls after trial setback (update) (SUPN:NASDAQ) - Seeking Alpha
Supernus reports less than super data for depression drug - pharmaphorum
Supernus Plunges On Failed Phase 2b Study Of SPN-820 In Treatment-resistant Depression - Nasdaq
Supernus Pharma sinks after depression drug fails mid-stage trial goal - TradingView
Supernus Pharma Sinks Premarket After Treatment-Resistant Depression Study Misses Primary Endpoint - Marketscreener.com
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression - GlobeNewswire
Supernus Announces Topline Results From Phase 2B Study In Adults With Treatment Resistant Depression - Marketscreener.com
Supernus' depression treatment fails mid-stage trial, shares plunge -February 18, 2025 at 04:49 pm EST - Marketscreener.com
Supernus' depression treatment fails mid-stage trial -February 18, 2025 at 04:35 pm EST - Marketscreener.com
Supernus Pharma stock tumbles after failed depression study By Investing.com - Investing.com Nigeria
Supernus Pharma stock tumbles after failed depression study - Investing.com India
Clinical Trial Setback: Supernus Depression Treatment Shows No Advantage Over Placebo - StockTitan
Cantor Fitzgerald Downgrades Supernus Pharmaceuticals to Neutral From Overweight, Cuts Price Target to $36 From $57 - Marketscreener.com
Supernus Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Yousif Capital Management LLC Sells 425 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Armenian Reporter
41,426 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Bought by Empowered Funds LLC - Defense World
Yousif Capital Management LLC Has $768,000 Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Access to Parkinson’s medication likely by summer: Supernus official - Parkinson's News Today
Janney Montgomery Scott LLC Makes New Investment in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Stephens Investment Management Group LLC Reduces Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 - Nasdaq
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Supernus Pharmaceuticals to Host Conference Call and - GlobeNewswire
Supernus Q4 Earnings: CEO and CFO Set to Unveil Full Year Performance Metrics - StockTitan
Investor Optimism Abounds Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) But Growth Is Lacking - Simply Wall St
Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade - MSN
Insider Selling: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Sells 9,477 Shares of Stock - MarketBeat
Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 1-Year HighHere's Why - MarketBeat
Supernus wins FDA approval for Parkinson’s pump on fourth try - MSN
Parkinson’s Disease Market is anticipated to Grow at a CAGR of 5.8% During the Study Period (2020-2034) by DelveInsight - The Globe and Mail
Supernus: New Approval Holds Promise Of Increased Growth (SUPN) - Seeking Alpha
US FDA approves Supernus' drug-device combination for Parkinson's disease - MSN
Top Supernus Executive Offloads Significant Stock Holdings! - TipRanks
Supernus Pharmaceuticals exec sells shares worth $376,236 By Investing.com - Investing.com Australia
Supernus Pharmaceuticals exec sells shares worth $376,236 - MSN
FDA nod at last for Supernus’ Parkinson’s infusion therapy - The Pharma Letter
Stifel maintains hold on Supernus, price target at $38 - MSN
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease - GlobeNewswire
Supernus Pharmaceuticals Inc (SUPN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Supernus Pharmaceuticals Inc 주식 (SUPN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Feb 04 '25 |
Sale |
39.70 |
9,477 |
376,237 |
10,149 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Jan 27 '25 |
Option Exercise |
29.61 |
2,573 |
76,187 |
12,722 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Jan 28 '25 |
Option Exercise |
29.61 |
700 |
20,727 |
10,849 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Jan 27 '25 |
Sale |
39.62 |
2,573 |
101,942 |
10,149 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Jan 28 '25 |
Sale |
39.62 |
700 |
27,734 |
10,149 |
3.23%
3.94%
자본화:
|
볼륨(24시간):